<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03617211</url>
  </required_header>
  <id_info>
    <org_study_id>JS-1566-2</org_study_id>
    <nct_id>NCT03617211</nct_id>
  </id_info>
  <brief_title>The Follow-up of Mesh/Native Tissue Complications Study(Part II)</brief_title>
  <official_title>A Multi-center Study: The Follow-up of Complications for Women Having Pelvic Reconstruction Surgery With Mesh/Native Tissue(Part II).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Obstetrics &amp; Gynecology Hospital of Fudan University，Shanghai Red House Obstetrics &amp; Gynecology Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospitals affiliated to the China PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University Affiliated Sixth People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital of Tongji University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuxi Obsetrics &amp; Gynecology Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fuzhou General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Jinan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Women's Hospital School Of Medicine Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Renmin Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Hospital Affiliated Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gansu Provincial Maternity and Child-Care Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yantai Yuhuangding Hospital，Medical College, Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The first Hospital Affiliated To Army Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Second University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangxi Maternal and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Coal Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the incidence and distribution of complications after different pelvic
      reconstruction surgeries (mesh/native tissue) in multi-centers. The investigators aimed to
      report and summarize the postoperative complications diagnosed in the prior 1 year, 3 years
      and 5 years respectively, according to the International Urogynecological
      AssociationInternational Continence Society(IUGA-ICS) Complication Classification
      Coding(Category-Time-Site coding system) .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are inferred to 27 tertiary hospitals with the complaint of de novo complications
      after pelvic reconstructive surgeries using mesh, tape and native tissue between June 2018
      and June 2023. The subjects include patients who accept treatment not only at 27
      participating hospitals but also from other hospital. And the date of surgeries carried is
      not restricted in the study period.

      This is a study of real world. The researchers focus to investigate the incidence of
      complications in clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The frequency and ratio of different postoperative complications</measure>
    <time_frame>1-year;3-year;5-year</time_frame>
    <description>Calculate the frequency(reported in number of cases) and ratio(reported in percentage, %) of different complications reported from 27 tertiary hospitals in the past year or 3 years or 5 years, respectively.The complications occurred after pelvic reconstructive surgeries, especially mesh/native tissue related,are classified by IUGA-ICS CTS(category-time-site)coding system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The distribution of complications after each kind of pelvic reconstructive surgery</measure>
    <time_frame>1-year;3-year;5-year</time_frame>
    <description>For each kind of surgery,the distribution of different postoperative complications, classified by the IUGA-ICS coding system, is expressed in frequency (reported in number of cases) and ratio(reported in percentage, %).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of various pelvic reconstructive surgeries under the same complication classification coding.</measure>
    <time_frame>1-year;3-year;5-year</time_frame>
    <description>Analyze and calculate the percentage of different surgical method when they present the complication with the same IUGA-ICS coding.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1530</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are inferred to 27 tertiary hospitals with the complaint of de novo complications
        after pelvic reconstructive surgeries using mesh, tape and native tissue between June 2018
        and June 2023. The subjects include patients who accept treatment not only at our
        participating hospitals but also from other hospital.And the date of surgeries carried is
        not restricted during the study period.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Patients are inferred to the clinic with the complaint of de novo complications
             after pelvic reconstructive surgeries with mesh,tape or native tissue.

          -  2) Pelvic reconstructive surgeries include but not limited to open/laparoscopic
             sacrocolpopexy (Y-shape tape/self-cut synthesized mesh), anterior, apical, posterior
             or total pelvic reconstruction with trans-vaginal mesh(commercial mesh kits or
             self-cut synthesized mesh), repair using native tissue(sacrospinous ligament fixation,
             high uterosacral ligament suspension, ischial spinous fascia fixation, the Lefort
             operation) and as well as anti-urinary incontinence surgeries(tension-free vaginal
             tape).

          -  3) Both primary and repeated pelvic surgery are included.

        Exclusion Criteria:

          -  If the same patient who developed complications after pelvic floor reconstructive
             surgeries has been diagnosed and reported in 27 participating hospitals, and again
             treated for &quot;the same code complication in other 26 hospitals, she will be ruled out.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lan Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuo Liang, MD</last_name>
    <phone>+86 13718879529</phone>
    <email>leahleung@foxmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lan Zhu, MD</last_name>
    <phone>+86 123911714696</phone>
    <email>zhu_julie@vip.sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of PLA General Hospital (304)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ke Niu, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Yongxian Lu, MD</last_name>
      <phone>+86 13520476024</phone>
      <email>yongxianlu@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yongxian Lu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuo Liang, MD</last_name>
      <phone>+86 13718879529</phone>
      <email>leahleung@foxmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Lan Zhu, MD</last_name>
      <phone>+86 13911714696</phone>
      <email>zhu_julie@vip.sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lan Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MD</last_name>
      <phone>+86 13609086710</phone>
      <email>xwzhang81341235@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaowei Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuxi Obstetrics &amp; Gynecology Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>241002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yijuan Huang</last_name>
    </contact>
    <contact_backup>
      <last_name>Jian Gong</last_name>
      <phone>+86 13812074116</phone>
      <email>gongjianwx@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jian Gong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Obstetrics &amp; Gynecology Hospital of Fudan University，Shanghai Red House Obstetrics &amp; Gynecology Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojuan Wang, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Keqin Hua, MD</last_name>
      <phone>+15921515900</phone>
      <email>huakeqin@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Keqin Hua, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>August 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>August 3, 2018</last_update_submitted>
  <last_update_submitted_qc>August 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pelvic reconstructive surgery</keyword>
  <keyword>mesh</keyword>
  <keyword>native tissue</keyword>
  <keyword>tape</keyword>
  <keyword>complications</keyword>
  <keyword>Category-time-site (CTS) coding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

